The Civica Rx Team
President & Chief Executive Officer
Martin VanTrieste is a former chief quality officer at Amgen who was recently named one of Modern Healthcare’s 100 Most Influential People in Healthcare and a leader on The Medicine Maker’s Power List of Industry Influencers. He brings over 35 years in the industry, with comprehensive experience in biopharmaceutical manufacturing, quality systems and related government regulations in the U.S. and around the world.
Under Martin’s leadership, Civica has expanded its membership to include over 50 health systems, representing over 1,350 hospitals across the U.S., and has more than 40 essential medications for hospitals, eleven of which are being used to treat COVID-19 patients. Most recently, Civica began providing its medicines to the U.S. Department of Veterans Affairs and the U.S. Department of Defense. During the peak of COVID-19 outbreaks in the U.S., Martin led efforts to deliver 2.1 million containers of Civica medicines to the country’s Strategic National Stockpile. In addition to working with quality supplier partners, Martin and the Civica team are working to advance generic drug production in the U.S. and are in the design phase for Civica’s future finished dosage generic manufacturing facility. The plant will be in Petersburg, Virginia and is part of a partnership with the U.S. Department of Health and Human Services and Phlow Corporation for end-to-end advanced manufacturing of essential medications.
Prior to joining Civica and Amgen before that, Mr. VanTrieste was with Bayer Healthcare’s Biological Products Division as vice president of worldwide quality and Abbott Laboratories as the vice president of quality assurance for the Hospital Products Division.
Mr. VanTrieste is the founder of Rx-360, an international nonprofit organization that enhances patient safety by increasing security and quality in the biopharmaceutical supply chain. He has also served as the Chairman of the Parenteral Drug Association (PDA) Board of Directors.
Mr. VanTrieste earned a Pharmacy degree from Temple University School of Pharmacy.
Chief Financial Officer
Eamon Fitzmaurice joins us most recently from Novartis Gene Therapies (previously named AveXis) and from vaccine companies Seqirus, Novartis Vaccines and pharmaceutical company Merck earlier in his career.
At Novartis Gene Therapies, Eamon served as Controller, Global Technical Operations shortly after joining the company as Plant Controller in 2018. Prior to working to working at Novartis Gene therapies, Eamon was Plant Manager for two years at an Oral Solid Dosage facility for Purdue Pharma. Eamon previously worked at Novartis Vaccines and led the US/Global vaccine finance organization through the sale of Novartis Vaccines to GlaxoSmithKline (GSK), including through the deal closure and integration with CSL. Prior to Novartis Vaccines, Eamon spent 23yrs with Merck in roles in both Finance and Operations (Production & Operational Excellence).
Eamon holds a B. Commerce from University College Cork, Ireland and a CMA from the Chartered Institute of Management Accountants in London, UK.
Chief Communications & Public Affairs Officer
With more than 25 years of experience in corporate communications and public relations agency environments, Debbi’s experience includes communications leadership roles in biopharma/healthcare, high tech, energy, government and hunger relief.
Most recently in biopharma with Alexion, Amgen, Novartis Vaccines (now GSK), and Shire (now Takeda), Debbi’s focus has been on patient-centered company narratives, media relations, corporate responsibility, employee communications, crisis and issues management, M&A communications, social media and brand creative. She has received award-winning recognition for her leadership of communications/change campaigns that helped companies solve business challenges and deliver improved and sustained results.
Debbi is a graduate of Syracuse University’s S.I. Newhouse School of Public Communications.
Russell A. Gall
Chief Manufacturing & Supply Chain Officer
Russell Gall serves on the executive leadership team of Civica Rx as Chief Manufacturing and Supply Chain Officer. Prior to Civica, Russ was actively involved in consulting throughout the pharmaceutical and medical device industry. He also currently serves on the Board of Directors of Hamlin Scientific.
As an Operations Executive with over 30 years in senior operations leadership roles in the pharmaceutical and medical device industries, Russ has had direct responsibilities for over 21 different global manufacturing sites. This has included controlled (Schedule 1-5) injectable drugs, radio-pharmaceuticals, potent compounds, cephalosporins, lyophilized products, specialty chemicals/active pharmaceutical ingredients, an extensive array of drug delivery systems, medical devices, all types of sterilization technologies, and all forms of molding and assembly operations. Russ’ functional responsibilities have included all aspects of Manufacturing, Quality, Research & Development, Supply Chain, Engineering, Maintenance, Finance, Human Resources, EH&S, Information Systems, Operational Excellence, and Contract Manufacturing.
Russ served as VP of Operations and General Manager for B. Braun Medical’s IV Solutions business in Irvine, CA, including all operations for a 1,450 employee, 4 building campus. As VP of Operations/GM for Teva Parenteral Medicines, Inc., he developed and implemented strategic plans for regulatory compliance remediation and return to market of key oncolytic products on FDA’s drug shortage list. As VP of Manufacturing Operations for Covidien, Russ led 9 global manufacturing facilities producing Contrast Media and Nuclear Medicines, generating sales of $1.1 billion. Russ was also a member of Hospira’s corporate executive team and, as VP of Operations, was responsible for the highest throughput injectable drug manufacturing site worldwide, including 2,600 employees and contributing to the generation of over $1 billion in sales.
Russ received two Bachelor of Science degrees (Microbiology and Packaging Engineering), both from Michigan State University, and is a recipient of a U.S. patent. He has also participated as a Board member of North Carolina Wesleyan College, Nash Community College Foundation, Boys & Girls Club of North Carolina, Rocky Mount Area Chamber of Commerce, and Rocky Mount Area United Way.
Chief R&D Officer
Scott Gochnour is a pharmaceutical industry leader serving on the executive leadership team with Civica Rx as the Chief Research and Development Officer. He brings extensive experience in developing and optimizing product performance and providing technical, quality and regulatory leadership to introduce quality products to market.
Prior to his position at Civica Rx, he was the Senior Vice President for Global Generic Research and Development (R&D) for Teva Pharmaceuticals, Inc. Additionally, he has held similar R&D leadership positions with Allergan, Actavis, Watson Pharmaceuticals and TheraTech for over 30 years in various research, product development, process engineering and management positions in R&D and production operations.
He was responsible for the global development and regulatory approval of both brand and generic complex dosages forms including drug/device combination products. He has had oversight for the manufacturing of pharmaceutical clinical and stability supplies in R&D pilot plants and commercial operations supporting regulatory submissions. His experience includes product formulation, process development, quality and compliance, regulatory affairs, equipment design and qualification, materials selection and evaluation, and scale-up/validation for commercial operations.
He graduated from the University of Utah with a Bachelor of Science degree in Materials Science and Engineering with emphasis in Biomaterials along with minors in Chemistry and Spanish. He is a member of the Engineering National Advisory Committee for the University of Utah and a former board member for BioUtah.
President of CivicaScript
Gina Guinasso has joined as the President of CivicaScript and is tasked with extending the successful Civica Rx model to the outpatient setting in order to dramatically lower the cost of select high-cost generic medications for individuals and families across the country.
Most recently Gina was the Senior Vice President of Commercial and Medicare Formulary Contracting Strategy at OptumRx, a UnitedHealth Group company. In this capacity, she led the day-to-day rebate negotiations for all internal and external pharmacy benefit management clients across all lines of business including commercial, Medicare part D, managed Medicaid, and fee for service Medicaid. Gina’s team was responsible for formulary strategy development and execution of manufacturer agreements for both pharmacy and medical benefit products and oversaw both traditional rebate and value-based contracts.
Prior to joining OptumRx, Gina spent over 20 years in the biopharmaceutical industry focused on leading market access account teams, federal markets, distribution strategy, specialty pharmacy networks, state and federal policy, patient assistance, and reimbursement strategy. Gina is a lawyer by training and has extensive experience contracting with commercial health plans, PBMs, Medicare and managed Medicaid plan sponsors, specialty pharmacies, wholesalers, 3PLs, and pharmaceutical manufacturers.
Gina is an active member of the Washington State Bar Association. She received her BA in International Business from Washington State University and her Juris Doctor from Seattle University School of Law.
Chief Quality & Regulatory Affairs Officer
Donna’s expertise spans worldwide operations, quality, and regulatory experience across vaccine, biological, pharmaceutical and device technologies where she has held positions of significant responsibility for Quality and GxP Compliance, including various roles in drug discovery, operations, and quality and regulatory affairs at Merck & Co., Bristol Myers Squibb and Lachman Consultants.
Donna is currently the Chief Quality & Regulatory Affairs Officer at Civica, Inc., a new independent not-for-profit company founded by health care systems and philanthropies to address critical generic drug shortages caused by market failures.
Chief Operating Officer
Ned is the Chief Operating Officer at Civica and is responsible for commercial operations, research and development, manufacturing/supply chain and business development. Prior to this role, Ned was the Chief Development Officer, responsible for developing and signing long term supply partnerships to prevent drug shortages and establish fair pricing.
Ned worked for Abbott for 32 years before joining Civica, where he had a strong track record of creating successful business opportunities by developing lasting partnerships between companies that capitalized on the strengths of both. Ned closed 40+ deals worth over $2.5 billion.
While at Abbott, Ned worked in 4 business divisions: Hospital Products, Pharmaceutical Products (now AbbVie), Nutrition and Corporate Mergers and Acquisitions.
Ned was the recipient of 4 President's Awards for outstanding accomplishments and was awarded the “Biggest Contributor to Earnings Per Share” for Abbott during one year. He is an inventor with 11 issued patents.
Ned received his Bachelor and Master of Science degrees in Chemical Engineering from North Carolina State University (Raleigh, NC). He and his wife, Gail, have 3 children and reside in Dublin, Ohio.
General Counsel & Chief Compliance Officer
Jennifer is General Counsel & Chief Compliance Officer of Civica, Inc., providing strategic legal advice designed to achieve business objectives and leading a team of lawyers working closely with the segment’s business units. She has extensive experience in complex licensing, advertising, healthcare compliance and crisis management.
Prior to joining Civica, Jennifer was Senior Vice President & General Counsel, Medical Segment of Cardinal Health. Jennifer lead a global team of lawyers to support the rapidly growing Medical Segment by providing strategic legal advice, including a $6.5B acquisition of Medtronic’s Patient Recovery Business.
Before moving to Cardinal Health, Jennifer spent 15 years at Abbott. Jennifer was the head of health policy, reimbursement, managed care and strategic alliances for Abbott Nutrition. Before being asked to lead health policy, she led the legal department for the division, helping the organization navigate the challenges of being both a healthcare and consumer goods company.
Jennifer previously was with the law firm of Squire Patton Boggs.
She received a bachelor’s degree in Government from Centre College and earned a juris doctor degree from Capital University.
She and her husband, Sloan, live in New Albany, Ohio, and enjoy endless hours of watching their three sons’ sporting events. Jennifer serves on the boards of National Church Residences and the New Albany Symphony Orchestra.
Chief Human Resources Officer
Kristopher Weidling (Kris), a strategic-thinking HR leader for global life sciences firms, showcases a superior track record of supporting an organization’s growth strategy while astutely managing talent and cultural change. He has proved to be a trusted advisor to organizational leadership in initiating innovative human capital management strategies and aligning HR best practices and processes with organizational objectives. Most importantly, he has accelerated transformation through leadership, attracting and developing the best talent and building a culture of engagement, agility, and innovation.
Most recently, as the Head of HR (Global Business Functions) at Astra Zeneca (AZ) Oncology, Kris championed the creation of an agile organizational culture while enabling 49% growth within the Oncology unit in 2018-2019. Here, he aligned all strategic HR scorecard initiatives with the AZ 2025 strategy of “Disruptive Innovation” to become the #1 Oncology company by 2025.
In 2016, after leading the Novartis Influenza Vaccines transformation to CSL Behring, Kris was promoted to Senior Director of Global Change Management to create and build the global change management organization to enhance the company’s capability and talent. Aligning the organization to achieve $10 billion in year-over-year growth by 2020, Kris secured executive buy-in to adopt a unified change management methodology that has improved organizational agility while recapturing $300,000 in consulting expenditures.
Enabling CSL Behring to retain over 90% of Novartis’ 130 top talent, Kris developed business-critical retention strategies for high-potential associates as Head of U.S. Human Resources, Global Talent Management and Organizational Development for Novartis Influenza Vaccines. His foresight and steady leadership eased Novartis’ employees into the new organization with minimal disruption. Before the acquisition, Kris served as Novartis Vaccines & Diagnostic’s Director of Human Resources from 2011 until 2015 with overlapping responsibility for the Global Human Resources Partner Technical Development from 2013 to 2015. As a member of senior management, he delivered a 20% improvement in employee engagement by applying his talents to unify the company culture while reducing turnover from 15.8% to only 8.6%.
Kris joined Novartis after a seven-year, high-impact tenure at Bayer Healthcare, a €1B biotech firm with a diverse body of over 1,000 employees creating biotherapeutic patient treatments. Through his efforts and focus on talent development, Bayer strengthened the sustainability of their talent pool, even negotiating contracts for 550 bargaining unit employees in partnership with the Labor Negotiations Team.
Before beginning his career path turn towards Life Sciences, Kris enjoyed several early career successes. From 2002 to 2004, he served as the Regional Human Resources Manager for Givaudan Flavors and Fragrances, a $2 billion global fragrance and flavor industry leader. Previously, Kris was the Regional Human Resources Manager for US Filter Corporation–one of the nation’s fastest growing businesses at the time.